Aeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at started coverage on shares of Aeterna Zentaris (NASDAQ:AEZSFree Report) (TSE:AEZ) in a research note released on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on Aeterna Zentaris from $28.00 to $15.00 and set a buy rating for the company in a research report on Monday, November 13th.

Check Out Our Latest Research Report on Aeterna Zentaris

Aeterna Zentaris Price Performance

AEZS stock opened at $1.80 on Friday. The company’s 50 day simple moving average is $1.97 and its 200-day simple moving average is $2.15. Aeterna Zentaris has a 52-week low of $1.36 and a 52-week high of $3.69. The firm has a market capitalization of $8.75 million, a P/E ratio of -0.37 and a beta of 1.57.

About Aeterna Zentaris

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Stories

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.